After completion of the treatments , the 36-month survival rate was 0.730 in the treatment group and 0.535 in the reference group ( p = 0.041 ) ; the average disease-free survival time was 48 months in the treatment group and only 37.5 months in the reference group ( p = 0.048 ) .